Truist analyst Richard Newitter raised the firm’s price target on Inspire Medical to $380 from $360 and keeps a Buy rating on the shares. Intra-quarter data points, including the firm’s Q2 hospital survey, increase confidence that procedure momentum will extend beyond Q2 into 2H23 with MedTech companies poised to deliver healthy beat and raises, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on INSP:
- Baird starts ‘market leader’ Inspire Medical at Outperform
- Inspire Medical initiated with an Outperform at Baird
- Inspire Medical price target raised to $360 from $340 at Piper Sandler
- Inspire Medical price target raised to $380 from $300 at Mizuho
- Inspire Medical price target raised to $350 from $300 at Stifel